Molecular testing for pulmonary TB (WHO): WHO: Xpert MTB/RIF or Xpert Ultra may be used as the initial test for pulmonary TB in adults when immediate treatment decisions are required and supplementary tests are unavailable or would delay treatment; a single Xpert Ultra may be used rather than two tests as initial testing in adults in the general population.
Applies to adults and children per WHO conditional/strong recommendations depending on setting.
Repeated Xpert testing (WHO): WHO: Do not repeat Xpert Ultra in adults with trace positive initial result; repeated testing in children depends on pretest probability and differs between Xpert MTB/RIF and Xpert Ultra recommendations.
Recommendations vary by age and pretest probability.
Truenat and Truenat MTB-RIF Dx (WHO): WHO: Truenat MTB or MTB Plus may be used as an initial diagnostic test for pulmonary TB instead of smear microscopy/culture; Truenat MTB-RIF Dx may be used to detect rifampicin resistance as initial test when positive.
Conditional recommendation; sensitivity may be lower in children.
Line probe assays (LPAs) (WHO): WHO: For sputum smear–positive specimens or cultured isolates, commercial molecular LPAs may be used instead of phenotypic DST to detect rifampicin and isoniazid resistance; LPAs are not recommended for direct testing of sputum smear–negative specimens, and conventional culture-based DST remains necessary for other agents.
Accuracy differs by drug and specimen type.
LF-LAM (WHO): WHO: LF-LAM is strongly recommended to assist diagnosis of active TB in HIV-positive inpatients with signs/symptoms or who are seriously ill, and suggested in outpatients with signs/symptoms and CD4 <100; WHO recommends against LF-LAM use in asymptomatic HIV-positive persons without symptom assessment or with unknown/higher CD4 counts.CD4 thresholds: <200 (inpatient strong), <100 (outpatient suggestion)
Follow WHO inpatient/outpatient distinctions and CD4-based recommendations.
AFB smear, culture, NAAT, and molecular DST (ATS/IDSA/CDC and NIH): Guidelines recommend AFB smear microscopy for all suspected pulmonary TB, both liquid and solid mycobacterial cultures for every specimen, NAAT on initial respiratory specimen, and rapid molecular DST for rifampin (± isoniazid) for specified patients; NIH recommends phenotypic DST to first-line drugs for all TB disease patients and confirmatory sequencing when rifampin resistance is detected by commercial NAA.
Laboratories must validate non–FDA-cleared methods for relevant specimens and submit isolates for public health/genotyping as required.
Extrapulmonary TB testing (ATS/IDSA/CDC): Perform mycobacterial cultures, NAAT, histology, AFB smear, and fluid studies (cell counts, chemistries, ADA, free IFNγ) on specimens from suspected extrapulmonary TB sites; submit culture isolates for genotyping.
ADA and IFNγ measurements are suggested by some guideline bodies for certain extrapulmonary sites.
LTBI testing — modality and age considerations (ATS/IDSA/CDC, AAP): For individuals ≥5 years, IGRA is recommended over TST when testing is warranted (especially with prior BCG or inability to return for TST reading); for healthy children <5 years, TST is suggested over IGRA; for children <2 years, TST preferred (AAP).Age cutoffs: <2 years, <5 years, ≥5 years
Guidelines discourage universal testing of low-risk individuals and emphasize targeted testing where a positive result would lead to treatment.
USPSTF screening recommendation: USPSTF (2023) recommends screening asymptomatic adults 18 years or older at increased risk for LTBI, emphasizing that those who screen positive must receive follow-up and treatment; frequency of screening depends on individual risk factors.
Recommendation applies to asymptomatic adults at increased risk, not to symptomatic patients or children/adolescents.
Molecular and WGS limitations (IDSA/ASM, TBNET/RESIST-TB): NAATs and molecular tests are adjuncts to culture; a negative NAAT does not rule out TB. WGS provides high discriminatory power but lacks interpretability for many mutations; culture-based DST remains the gold standard for many agents.
Molecular results may need phenotypic confirmation; reference laboratories recommended for complex DST.